Johannes Levin
banner
johanneslevin.bsky.social
Johannes Levin
@johanneslevin.bsky.social
Professor for Clinical Neurodegeneration at LMU Munich; Deputy lead of clinical research at German Center for Neurodegenerative Diseases (DZNE), site Munich; Chief Medical Officer at MODAG GmbH. --> Passionate about therapy development, Bayern & Betis
Alzheimer ist die häufigste Todesursache bei Menschen mit Down-Syndrom.

Die Alzheimer Forschung Initiative hat hierzu ein neues Video veröffentlicht.

Wir freuen uns sehr, dass die spezialisierte Ambulanz an der Neurologie der LMU München erwähnt wird.

👉 Zum Video: youtu.be/UovdbwD44F0?...
August 30, 2025 at 3:27 PM
It was a great honor to host the #GENFI summer meeting 2025. Two days of excellent talks and inspiring discussions. Thanks for coming to Munich and safe travels to everyone.
June 7, 2025 at 4:57 PM
¡¡Día histórico para el Betis!! ¿Cómo va a quedar esto? ¡Vamos con todooo! 💚⚽️

What a historic day for Betis!! How’s this gonna end? Let’s gooo! 💚⚽️
May 28, 2025 at 10:11 AM
I have a new favorite conference: dsad-adad.com See you in Barcelona next year for the 3rd edition of DSAD-ADAD.
Genetically Determined Alzheimer Disease: Cross-fertilization between Down Syndrome & Autosomal Dominant Alzheimer Disease
dsad-adad.com
May 24, 2025 at 2:33 PM
Reposted by Johannes Levin
Washington University-led research shows a small group of participants in an Alzheimer’s study experienced a significant delay in the onset of symptoms.
St. Louis study shows that drug may prevent Alzheimer’s. NIH slowdowns threaten future research
Washington University-led research shows a small group of participants in an Alzheimer’s study experienced a significant delay in the onset of symptoms.
www.stltoday.com
March 20, 2025 at 11:45 AM
TOPAS-MSA is launching in Japan. The investigator meeting took place yesterday and today in Yokohama. Japan’s strong tradition in MSA research and the outstanding dedication of the trial sites created an exciting environment. We’re thrilled to have you on board. clinicaltrials.gov/study/NCT065...
March 30, 2025 at 5:12 AM
We did it and now it is published: A highly Lewy-fold selective and quantitative Synuclein Aggregate Amplification Assay (SAA). Huge thanks to the amazing teams at MODAG GmbH, LMU Munich, and Bologna University!
rdcu.be/eaISM
A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease
rdcu.be
February 21, 2025 at 5:23 PM
The TOPAS-MSA study investigating emrusolmin for disease modification in Multiple System Atrophy (MSA) is starting in Europe. Impressions from the investigator meeting in Barcelona (Spain).
www.clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/
February 12, 2025 at 2:42 PM
Reposted by Johannes Levin
The risk of developing dementia may be much higher than previously thought, a study published in the journal Nature Medicine has found.
Dementia risk may be twice as high as Americans live longer, study finds
Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in the U.S. is expected to double by 2060.
www.nbcnews.com
January 13, 2025 at 5:23 PM
One of the largest health insurance companies in Germany shows interest in Alzheimer’s disease in individuals with Down Syndrome: www.aok.de/pk/magazin/k...
Alzheimer und Down-Syndrom: So hängen sie zusammen
Menschen mit Down-Syndrom erkranken häufiger an Alzheimer. Warum das so ist und was das für die Behandlung bedeutet, erklärt unser Experte.
www.aok.de
January 9, 2025 at 6:01 PM
So well deserved. An example to follow for all of us.
January 6, 2025 at 8:02 PM
Reposted by Johannes Levin
Still on my 25-year crusade to end all two-sided alpha testing in superiority trials. It's something simulating clinical trials brings out as just plain silly.
December 1, 2024 at 2:55 PM
Reposted by Johannes Levin
A interesting body of commentary from key people on this critically important topic. Definitely worth a read. Is removing substantial amyloid plus meeting safety targets enough to approve a treatment for #Alzheimer's? #ENDALZ

www.alzforum.org/news/researc...
Is It Time to Approve Drugs Based on Amyloid Removal? | ALZFORUM
www.alzforum.org
December 17, 2024 at 10:50 PM
Difficult match in complicated moment for the most special club in Spanish football.
Will we see Isco back on the pitch?

www.abc.es/deportes/alf...
Canales: «Al Betis lo quiero mucho»
El centrocampista de Rayados recuerda con cariño su época como verdiblanco y no olvida ni a sus compañeros ni a sus trabajadores
www.abc.es
December 7, 2024 at 2:36 PM
Reposted by Johannes Levin
🎨 In case anyone need…

The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏!

Check it out 👇
bioart.niaid.nih.gov
November 23, 2024 at 3:50 PM
International break is over. Día del Betis! «Los sentimientos estarán a flor de piel» www.abc.es/deportes/alf...
Vamooos!! Mucho Betis!
Joaquín y el Valencia - Betis tras la DANA: «Los sentimientos estarán a flor de piel»
El portuense recuerda la ayuda verdiblanca a los afectados y anuncia más actividades este fin de semana a través de la Fundación Real Betis
www.abc.es
November 23, 2024 at 11:33 AM
Reposted by Johannes Levin
Day two on @bsky.app and I'll go ahead say I'm LOVING IT. Fellow #scientists and #Alzheimer's and #ADRD peeps: Tell everyone you know to get on over here! The skies are blue once again!
a man in a suit and tie is sitting at a desk and saying `` i love it '' .
ALT: a man in a suit and tie is sitting at a desk and saying `` i love it '' .
media.tenor.com
November 18, 2024 at 11:17 PM